MS- Ofatunumab DI

Question 1

Ofatumumab brand name

Answer 1

Kesimpta

Question 2

Ofatumumab indications

Answer 2

CIS, RRMS, active SPMS

Question 3

Kesimpta MoA

Answer 3

Binds specifically to the extracellular loops of the CD20 molecule –> potent complement-dependent cell lysis and antibody-dependent cell-mediated toxicity in cells that overexpress CD20

Question 4

Kesimpta dosing

Answer 4

20mg SQ qweek x3 doses, then 20mg qmonth on week 4

Question 5

Areas you can administer Kesimpta

Answer 5

SQ in abdomen, thigh, outer upper arm

Avoid blemished skin

Question 6

The first dose of Kesimpta should be administered with who?

Answer 6

A HCP! Subsequent doses can be taken at home!

Question 7

Kesimpta ADEs

Answer 7

Decrease in immunoglobulin levels
Increased risk of URTI and UTIs
Systemic and local injection reactions

Infection, serious infection, injection site reactions, HA, URTI, UTIs, decreased serum immunoglobulins, back pain

Question 8

Live vaccines, live attenuated vaccines and Kesimpta

Answer 8

Administer the vaccines 4 weeks before starting treatment

Question 9

Non-live vaccines and Kesimpta

Answer 9

Administer the vaccine 2 weeks before starting treatment

Question 10

Kesimpta monitoring

Answer 10

Quantitative serum immunoglobulins prior to therapy initiation
Latent hepatitis and TB infections in countries with high TB burden
HBV screening prior to initiation
Females of childbearing age: use effective contraception

Question 11

Storage conditions for intact Kesimpta vials, Sensoready pens, and prefilled syringes

Answer 11

Fridge, DO NOT FREEZE, PROTECT FROM LIGHT

Before administration, allow to cool to room temperature for 15-30 minutes